TRDA
NASDAQ · Biotechnology
Entrada Therapeutics Inc
$6.80
+0.16 (+2.41%)
Open$6.64
Previous Close$6.64
Day High$6.84
Day Low$6.64
52W High$16.45
52W Low$5.02
Volume—
Avg Volume350.4K
Market Cap267.88M
P/E Ratio—
EPS$-3.97
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+165.3% upside
Current
$6.80
$6.80
Target
$18.04
$18.04
$12.20
$18.04 avg
$27.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 24.39M | 42.90M | 41.05M |
| Net Income | -137,894,921 | 8.98M | 10.98M |
| Profit Margin | -565.5% | 20.9% | 26.8% |
| EBITDA | -147,538,755 | 15.57M | 16.71M |
| Free Cash Flow | — | 11.03M | 8.57M |
| Rev Growth | — | +8.9% | +15.8% |
| Debt/Equity | — | 0.18 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |